Biosite plans further data as FDA panel rejects heart test
This article was originally published in Clinica
Rapid test manufacturer Biosite Diagnostics has said it could file an amended PMA for US approval of its Triage BNP diagnostic for heart failure as early as late summer. The company's original application was rejected by an FDA advisory panel on March 24 by six votes to three after "major concerns" with the clinical data from US trials. The agency normally follows its panel's advice.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.